News MoonLake Immunotherapeutics Shares Double After Positive Trial Results MoonLake Immunotherapeutics saw its shares double to $55 in premarket trading following positive trial results. The global Phase 2 trial evaluated the safety ... By Artur FernandoJune 29, 20230
BlackRock is reviewing TechBerry and negotiating a possible full or partial acquisition of the company June 20, 2024